Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis RALEIGH-DURHAM, NC , June 15, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing therapies for rare pulmonary and rheumatic diseases with high unmet...

Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations Raleigh-Durhan, NC, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today...

Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for Development of ACG-701 as Medical Countermeasure Against Melioidosis Raleigh-Durham, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet medical need, ...

Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline RALEIGH-DURHAM, N.C , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and orphan diseases, today announced...